[ 104 ] | INTERVIEW
maceutical company in Hyderabad. We have deepened our relationship with that company and we have established new relationships with companies in Mumbai, Bengaluru, Hyderabad and Ahmedabad.
“MICROPORE IS LOOKING AT INVESTING SIGNIFICANTLY IN INDIA”
What is the amount you are planning to invest in India? We cannot divulge the exact amount but it would be sufficient for the conduct of business properly. We will be investing in laboratories, people who will run them and an additional team for marketing. We have investments in supply chain partners who have been very reliable and we are happy with them.
Dai Hayward, Chief Executive Officer, Micropore Technologies Ltd. shares his insights on the Indian subsidiary focus, India investment, and new technologies. Excerpts of the interview: tion. We are very close to doing business directly between the Indian customers and our own company in India. We plan to make available all our technologies and products including enhanced formulations available to the entire Indian market. The plan will be to roll it out slowly over a while. We already have been doing business with the pharmaceutical and agrochemical sectors.
DAI HAYWARD
CHIEF EXECUTIVE OFFICER, MICROPORE TECHNOLOGIES LTD. Micropore Technologies is in the process of establishing its subsidiary in India. What will be the focus of the Indian subsidiary? Micropore Technologies is all about precision formulations. We have the technology for doing that which we have already introduced to the Indian market about 4-5 years ago. And with the growth of business in India, we felt it important to establish a subsidiary here. We have registered in Hyderabad and are going through the final formalities of setting it up including obtaining our GST registra-
When in 2021, are you planning to set up this subsidiary and when should it be operational? Any timelines?
What will be the key activities of this laboratory? The laboratory will help the local customers with their formulation challenges. For example, making lipid nanoparticles, liposomes, vaccines and gene therapy treatments. We will demonstrate our technologies and work with the Indian customers in the Indian market in an Indian laboratory. Our homegrown technology solutions are very much fitting with the Make in India call by the Prime Minister of India.
“We have deepened our relationship with that company and we have also established new relationships with companies in Mumbai, Bengaluru, Hyderabad, and Ahmedabad”
As soon as we will finish the registration for GST and similar other processes, everything will be operational and ready to roll.
In 2018, you have done your first sale to a pharmaceutical company in India. How has been your journey to date and how is the Indian company performing? The sale we made in 2018 was to a phar-
In terms of manpower, how many people are you planning to recruit in your R&D lab? We will probably recruit three to four experts in the next 12 months and depending on the success, I shall expect it to grow rapidly after that.
Do Micropore Technologies offer a new crystallization process principally targeted at API manufacturers who are working to restore APIs from China? How will this technology help Indian companies? The technology we have allows one to produce crystals of the right size with minimal downstream processing and no
